Частота госпитализаций пациентов при длительном лечении инъекциями пролонгированного рисперидона
Penghua Shu, П. м Льорка, И. Дюшесн et al. · Социальная и клиническая психиатрия · 2006
Background: Patients with schizophrenia or schizoaffective disorder are at high risk of relapse, which may lead to hospitalization. Objective: To assess hospitalization rates during 1 year of treatment with long-acting risperidone injection. Subjects, Materials, and Methods: The study was a 1-year, international, open-label trial of long-acting risperidone injection in inpatients and outpatients classified as stable. Patients had to have been receiving a stable dose of their current antipsychotic medication for at least 4 weeks before entering the study. After a 2-week run-in (oral risperidone, 1-6 mg/day), patients entered a 12-month, open-label phase in which they received long-acting risperidone injection 25 mg, 50 mg, or 75 mg, every 2 weeks, depending on their previous dose of oral risperidone. Oral risperidone supplementation was supplied for the first 2 to 3 weeks. The dose of long-acting risperidone injection could be increased or decreased by the investigator if necessary. Results: Of 397 patients who received a modal dose of long-acting risperidone injection, 25 mg or 50 mg (the commercially available dose range), 24% were inpatients and 76% were outpatients at baseline. The number of patients requiring hospitalization decreased continuously and significantly, from 38% in the 3 months before treatment to 12% during the last 3 months of treatment (p
Cited by 0 works.